1 / 26

Continuous Flow Mfg Skip-Lot Sampling Closing Presentation

Continuous Flow Mfg Skip-Lot Sampling Closing Presentation. Topic A Lynn Torbeck Frank Gomez Domenick Amato. Continuous flow manufacturing Batches and lots Suppliers “Skip Test” vs. “Skip Lot” Statistical Sampling Plans USP Supplier Relationships. Overview.

jacob
Télécharger la présentation

Continuous Flow Mfg Skip-Lot Sampling Closing Presentation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Continuous Flow MfgSkip-Lot SamplingClosing Presentation Topic A Lynn Torbeck Frank Gomez Domenick Amato

  2. Continuous flow manufacturing Batches and lots Suppliers “Skip Test” vs. “Skip Lot” Statistical Sampling Plans USP Supplier Relationships Overview

  3. Defining Continuous Process: Long term vs. short term The size of the material exceeds the capacity of the equipment The reactor full vs. ongoing production Discrete activity Continuous Flow Mfg

  4. Common in chemicals to campaign large batches Sampling and testing procedures may help define a continuous vs. batch process. Continuous Flow

  5. 210.3(b)(2) See definition of a batch Discrete volume vs. ongoing production See definition of a lot Lot is equal to a batch Or, lot is a sub portion of a batch Batches and Lots

  6. Within the context of the GMP’s a batch or lot can be defined as part of the quality agreement between the supplier and customer The batch must have uniform characteristics regardless of contract. Batches and Lots

  7. A change in the manufacturing, a process upset, may cause a change in the definition of the batch size. A batch can be defined by a predetermined interval, i.e. 6 hrs. Drug manufacturer is responsible for assuring compliance. Batches and Lots

  8. Excipient suppliers are not generally qualified, but the Excipient manufacturers are qualified/ certified. Need to know the supply chain including shipping and distribution. Audit the excipient manufacturer for compliance. Suppliers

  9. Depending on the number of lots purchased choose an interval for certifying the reliability of excipient manufacturer’s C of A Interval of 1, 3 times/yr Test ten then every tenth lot or one per yr. Drug manufacturer must test critical performance criteria. It may or may not be on the C of A. Suppliers

  10. Drug manufacturer determines what are critical excipients. The extent to which GMP’s controls are applied depend on criticality and usage or intended use as determined by the drug manufacturer. Critical Excipients

  11. Different drug manufacturer have different acceptance criteria for raw material delivery and batch definition. For some every shipment is a different batch, test all characteristics. Defining a Batch

  12. Other companies do an ID test and accept other tests from the CoA of the previous shipments of the same supplier batch. Quality history should not be used to sunset testing of critical attributes “Skip Testing”

  13. Sampling Variables with a spec range Little or no attribute testing Z1.4 and Z1.9, S1 are not used. Square root of (N) +1 is used Composite testing for variables test Individual samples for ID but not for variables test All specification testing must be done. Sampling Plans

  14. Can be a valid sampling plan Lot size Sample size Accept on zero Reject on one defect or failure Matches Z1.4 GL I sample sizes Square root of (N) +1

  15. In practice, testing is accept on zero and reject on one. Statistical “Skip Lot” testing is not being done because an ID must be done on all batches. Other tests may not be done as the supplier is doing the tests, “skip testing.” Sampling Plans

  16. If the supplier doesn't do the specification tests then the drug manufacturer must do the test. Sampling Pre delivery sample Very little Tail gate sample Very little Pull on site Common Sampling Plans

  17. API, 10 lots initial, then one a year Excipients, 5 lots initial then one a year A few companies use statistics to determine the skip testing. Skip Testing

  18. Some companies are using control charts and process capability, Cpk, to monitor and trend data collected. Some suppliers allow the customers to see the control charts. Trending

  19. The USP can change the monograph given adequate scientific justification. The drug manufacturer may have to change the filing. Time span for a change is 9-24 months. Committees are volunteers. USP

  20. Change to a non monograph method may require an update of the drug master file. If a customer makes a change to a test for a critical parameter they may have to update the drug filing. Changes to Methods

  21. Need a strong trusting relationship between supplier and customer. Supplier relationship is critical for supplier certification. Excipient manufacturer notifies customer of changes. ISO document has criteria for supplier grades, A, B, and C. Supplier Relationships

  22. If a drug mfg identifies a critical quality attribute that is not a USP test then the mfg must develop a test. Look at ICH and FDA guidances to determine what are the critical attributes, and FDA SUPAC guidances to determine the levels of changes stated therein. Critical Quality Attributes

  23. Continuous flow processes can meet the GMP definitions of batches and lots. Within the GMPs for continuous flow processes, a batch or lot can be defined by an agreement between the supplier or manufacturer and customer. Conclusion

  24. Square root of (N)+1 is being used correctly for composite samples. Square root of (N)+1 can be a valid sampling plan. Statistical Skip Lot testing can not be used since each lot must at least be tested for ID. Conclusions

  25. Many companies are doing “skip test” procedures. Did not find any practice that needs to be changed or modified. Conclusions

  26. Confusion exists because most excipient manufacturers do not conduct all tests because of their controls. If they do not run the test it must be clearly indicated since some one will need to run that test. (21 CFR 211.84) In today’s environment of PAT do all tests really need to be run if excipient manufacturers have the systems under control. (21 CFR 211.84) Does 21 CFR 211.84 need to be revised to allow for PAT? Closing Questions / Comments

More Related